Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group

Özet

Purpose Atezolizumab has been shown to be efective and safe in randomized trial in the frst-line treatment of extensivestage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efcacy and safety of atezolizumab combined with chemotherapy in the frst-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a frst-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (p=0.002) and number of metastatic sites (p=0.001) were associated with PFS and pack-year of smoking (p=0.05), while ECOG-PS (p=0.03) and number of metastatic sites (p=0.001) were associated with OS. Hematological side efects were common and toxicities were manageable. Conclusion This real-life data confrm the efcacy and safety of atezolizumab in combination with chemotherapy in frstline treatment of extensive-stage SCLC.

Açıklama

Anahtar Kelimeler

Atezolizumab, Small Cell Lung Cancer, Immunotherapy, PD-L1

Kaynak

Journal of Cancer Research and Clinical Oncology

WoS Q Değeri

Q2

Scopus Q Değeri

Q1

Cilt

Sayı

Künye

Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group. J Cancer Res Clin Oncol. 2022 Jun 11. doi: 10.1007/s00432-022-04087-x. Epub ahead of print. PMID: 35689097.